drugset / Trial / NCT00121225

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

NCT00121225

Phase 2 Completed 32 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2005-09
Primary completion
2009-03
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 400 mg Oral